At the 2023 ASCO meeting, RudaCure registered an abstract for RCI002, its 化疗引起的疼痛 treatment compound, and presented the 临床前结果 of the drug to many international researchers.
In particular, this attendance was as part of the KONECT 临床试验 delegation, which provided a venue to discuss clinical topics related to ADC and CAR-T in the oncology field, along with related diseases and 副作用, as well as an opportunity to introduce the 疗效 of RCI002 in 疼痛治疗药.
RudaCure Clinical Director Yuseung Ha explaining RCI002 to a WRNMC Oncology Pharmacist
RCI002 Development Project Owner Manager Minjung Kim, Abbvie RA representative, WRNMC Pharmacist, Clinical Director Yuseung Ha
데일리팜: 데일리팜